TL;DR
This multicenter, randomized controlled trial demonstrates that the Chinese-manufactured botulinum toxin, Hengli® (BTX-A), is a safe and highly effective treatment for overactive bladder (OAB) in patients who fail standard oral therapies. The study found that a single 100 U intradetrusor injection significantly reduced daily bathroom trips and urgency episodes while remaining well-tolerated by the Chinese patient population.
What Problem Does This Paper Address?
Overactive bladder (OAB) is a chronic, disabling condition characterized by a sudden, uncontrollable urge to urinate, often leading to high frequency and nighttime disruptions. In China, nearly 24% of adults over 40 suffer from OAB.
While oral anticholinergic drugs are the first line of defense, they often fail due to poor efficacy or "intolerable" side effects like severe dry mouth and constipation. While the global brand Botox® is well-established for OAB, there has been a lack of large-scale, high-quality randomized clinical trials specifically for the domestic Chinese brand, Hengli®. This paper aims to bridge that gap, providing the clinical evidence needed to validate Hengli® as a viable, localized alternative for refractory OAB.
Methods
The researchers conducted a multicenter, prospective, randomized, double-blind, placebo-controlled trial across 17 sites in China.
- Participants: 216 patients (18–75 years old) with idiopathic OAB who were inadequately managed by oral medications.
- Randomization: Patients were randomized 2:1 to receive either 100 U of Hengli® BTX-A (n=144) or a placebo (n=72).
- Procedure: The drug was administered via 20 intradetrusor injections (the muscle of the bladder wall), each 2 mm deep, avoiding the bladder neck.
- Evaluation: The primary endpoint was the change in daily micturition (urination) episodes at week 6. Secondary endpoints included urgency frequency, urinary incontinence (UI) episodes, and quality of life (QoL) scores.
Datasets
As a clinical trial, the "dataset" consists of the patient cohorts recruited across the 17 Chinese medical centers.
- ITT (Intention-to-Treat) Population: 216 patients.
- FAS (Full Analysis Set): 213 patients (142 in the BTX-A group, 71 in the placebo group).
- Safety Population: All patients who received at least one dose of the treatment.
Key Insights and Ideas
- Dual-Action Mechanism: The paper highlights that BTX-A works through two pathways: it inhibits the release of acetylcholine to suppress involuntary muscle contractions (motor) and blocks the release of neurotransmitters like ATP and substance P to dampen the "urge" signals (sensory).
- The "OAB-Dry" Phenotype: Interestingly, 70% of Chinese OAB patients present without urinary incontinence (known as "OAB-dry"). This study confirms that BTX-A is highly effective for this specific demographic, not just those suffering from leakage.
- Dosing Precision: The use of 100 U appears to be a "sweet spot." It provided significant symptomatic relief while keeping the rate of urinary retention (the inability to empty the bladder) low enough that only one patient in the study required a catheter.
- Regional Bioequivalence: The study suggests that Hengli® performs comparably to international brands like Botox® in terms of efficacy and safety, offering a potentially more accessible option for the Chinese healthcare system.
Key Results
The results at the 6-week mark were statistically significant across nearly all primary and secondary metrics:
- Frequency Reduction: The BTX-A group saw a reduction of 3.28 micturitions per day, compared to only 1.43 in the placebo group (p = 0.003).
- Urgency Relief: Daily urgency episodes dropped by 2.40 in the BTX-A group vs. 0.70 in the placebo group.
- Volume Increase: The average volume of urine per void increased significantly in the BTX-A group by week 12, indicating the bladder could hold more comfortably.
- Safety: The most common adverse events were increased post-void residual (PVR) urine volume (19.01%) and urinary tract infections (13.38%). Most were mild to moderate and resolved without major intervention.
Limitations and Future Work
- Short-Term Primary Focus: While the study tracked patients up to 24 weeks in an extended phase, the primary efficacy was measured at 6 weeks. OAB is a lifelong condition, and longer-term data on the duration of a single injection's effect would be beneficial.
- No Head-to-Head Comparison: The study compared Hengli® to a placebo, not directly to other BTX-A brands like Botox® or Dysport®. A head-to-head trial would be the gold standard for proving bioequivalence.
- Future Directions: The authors suggest further research into the molecular mechanisms of how BTX-A affects the bladder's sensory pathways and long-term studies on the safety of repeated injections over several years.
Summary updated